Compare Incyte Corporation (INCY) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs State Street SPDR S&P Homebuilders ETF — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while State Street SPDR S&P Homebuilders ETF trades at $94.77 (market cap $1.49B). The key difference: Incyte Corporation is far larger — about 15.3× State Street SPDR S&P Homebuilders ETF's market cap, and Incyte Corporation is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and State Street SPDR S&P Homebuilders ETF for 33 Days on average.
| INCY | XHB | |
|---|---|---|
Market Cap | $22.85B | $1.49B |
Volume | 1,927,029 | 2,445,587 |
Sector | Health | Broad Market / Factor |
52-Week High | $129.93 | $121.36 |
52-Week Low | $83.80 | $94.86 |
Typical Hold Time | 33 Days | 33 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
XHB (SPDR S&P Homebuilders ETF) trades at $94.77, down 0.13% with a bearish technical outlook from moving averages. The ETF tracks homebuilder stocks facing headwinds from rising mortgage rates near 7%, though recent news highlights potential buying opportunities amid sector undervaluation. Technical indicators show neutral oscillators but bearish momentum with support at $94 and resistance at $96.
The housing market faces mixed signals with rising rates pressuring affordability, but legislative support and institutional interest suggest long-term potential. Key risks include mortgage rate volatility and economic sensitivity, while analyst coverage emphasizes sector recovery prospects. Investment appeal hinges on housing market stabilization and policy impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
